Observing the invisible: successful tumor immunity in humans, Nature Immunology, vol.4, issue.3, p.201, 2003. ,
DOI : 10.1038/ni0303-201
Paraneoplastic Syndromes Involving the Nervous System, New England Journal of Medicine, vol.349, issue.16, pp.1543-1554, 2003. ,
DOI : 10.1056/NEJMra023009
Tumor-specific killer cells in paraneoplastic cerebellar degeneration, Nature Medicine, vol.182, issue.11, pp.1321-1324, 1998. ,
DOI : 10.1016/S0896-6273(00)80562-0
URL : https://hal.archives-ouvertes.fr/pasteur-01402438
Detection and treatment of activated T cells in the cerebrospinal fluid of patients with paraneoplastic cerebellar degeneration, Annals of Neurology, vol.21, issue.1, pp.9-17, 2000. ,
DOI : 10.1002/1531-8249(200001)47:1<9::AID-ANA5>3.0.CO;2-I
URL : https://hal.archives-ouvertes.fr/pasteur-01402433
Dendritic cells and the control of immunity, Nature, vol.392, issue.6673, pp.245-252, 1998. ,
DOI : 10.1038/32588
Autoantigens targeted in systemic lupus erythematosus are clustered in two populations of surface structures on apoptotic keratinocytes, Journal of Experimental Medicine, vol.179, issue.4, pp.1317-1330, 1994. ,
DOI : 10.1084/jem.179.4.1317
Onconeural antigens and the paraneoplastic neurologic disorders: at the intersection of cancer, immunity, and the brain., Proceedings of the National Academy of Sciences, vol.93, issue.10, pp.4529-4536, 1996. ,
DOI : 10.1073/pnas.93.10.4529
Dendritic cells acquire antigen from apoptotic cells and induce class I-restricted CTLs, Nature, vol.392, issue.6671, pp.86-89, 1998. ,
DOI : 10.1038/32183
Taming cancer by inducing immunity via dendritic cells, Immunological Reviews, vol.61, issue.1, pp.129-150, 2007. ,
DOI : 10.1016/j.cell.2006.01.007
The Three Es of Cancer Immunoediting, Annual Review of Immunology, vol.22, issue.1, pp.329-360, 2004. ,
DOI : 10.1146/annurev.immunol.22.012703.104803
Efficient Presentation of Phagocytosed Cellular Fragments on the Major Histocompatibility Complex Class II Products of Dendritic Cells, The Journal of Experimental Medicine, vol.61, issue.11, pp.2163-2173, 1998. ,
DOI : 10.1016/0167-5699(92)90198-G
Cell-Associated Ovalbumin Is Cross-Presented Much More Efficiently than Soluble Ovalbumin In Vivo, The Journal of Immunology, vol.166, issue.10, pp.6099-6103, 2001. ,
DOI : 10.4049/jimmunol.166.10.6099
and CD36, and Cross-present Antigens to Cytotoxic T Lymphocytes, The Journal of Experimental Medicine, vol.265, issue.7, pp.1359-1368, 1998. ,
DOI : 10.1126/science.270.5241.1500
URL : https://hal.archives-ouvertes.fr/pasteur-01402441
Apoptotic Cells Deliver Processed Antigen to Dendritic Cells for Cross-Presentation, PLoS Biology, vol.176, issue.6, p.185, 2005. ,
DOI : 10.1371/journal.pbio.0030185.sd001
URL : https://hal.archives-ouvertes.fr/inserm-00708471
Dendritic cell maturation is required for the cross-tolerization of CD8+ T cells, Nat Immunol, vol.9, pp.1-8, 2001. ,
Biological Therapy with Oncolytic Herpesvirus, Adv Exp Med Biol, vol.622, pp.221-233, 2008. ,
DOI : 10.1007/978-0-387-68969-2_18
Gene therapy of malignant gliomas: a pilot study of vaccination with irradiated autologous glioma and dendritic cells admixed with IL-4 transduced fibroblasts to elicit an immune response, Hum Gene Ther, vol.12, pp.575-595, 2001. ,
Surgery and adjuvant dendritic cell-based tumour vaccination for patients with relapsed malignant glioma, a feasibility study, British Journal of Cancer, vol.61, pp.1656-1662, 2004. ,
DOI : 10.1038/sj.bjc.6602195
Vaccination Elicits Correlated Immune and Clinical Responses in Glioblastoma Multiforme Patients, Cancer Research, vol.68, issue.14, pp.5955-5964, 2008. ,
DOI : 10.1158/0008-5472.CAN-07-5973
Clinical Evaluation of Dendritic Cell Vaccination for Patients with Recurrent Glioma: Results of a Clinical Phase I/II Trial, Clinical Cancer Research, vol.11, issue.11, pp.4160-4167, 2005. ,
DOI : 10.1158/1078-0432.CCR-05-0120
Vaccination with Tumor Lysate-Pulsed Dendritic Cells Elicits Antigen-Specific, Cytotoxic T-Cells in Patients with Malignant Glioma, Cancer Research, vol.64, issue.14, pp.4973-4979, 2004. ,
DOI : 10.1158/0008-5472.CAN-03-3505
Induction of immunity to prostate cancer antigens: results of a clinical trial of vaccination with irradiated autologous prostate tumor cells engineered to secrete granulocyte-macrophage colony-stimulating factor using ex vivo gene transfer, Cancer Res, vol.59, pp.5160-5168, 1999. ,
Dendritic Cells Loaded With Killed Allogeneic Melanoma Cells can Induce Objective Clinical Responses and MART-1 Specific CD8+ T-cell Immunity, Journal of Immunotherapy, vol.29, issue.5, pp.545-557, 2006. ,
DOI : 10.1097/01.cji.0000211309.90621.8b
Dendritic cells loaded with killed breast cancer cells induce differentiation of tumor-specific cytotoxic T lymphocytes, Breast Cancer Research, vol.50, issue.4, pp.322-330, 2004. ,
DOI : 10.1002/jcb.240500403
Assessment of fusion cells from patient-derived ovarian carcinoma cells and dendritic cells as a vaccine for clinical use, Gynecologic Oncology, vol.99, issue.2, pp.462-471, 2005. ,
DOI : 10.1016/j.ygyno.2005.07.019
Vaccination of pediatric solid tumor patients with tumor lysate-pulsed dendritic cells can expand specific T cells and mediate tumor regression, Cancer Res, vol.61, pp.8513-8519, 2001. ,
Dendritic Cell???Based Vaccination Against Cancer, Hematology/Oncology Clinics of North America, vol.20, issue.3, pp.689-710, 2006. ,
DOI : 10.1016/j.hoc.2006.02.011
Opinion: Death-defying immunity: do apoptotic cells influence antigen processing and presentation?, Nature Reviews Immunology, vol.104, issue.3, pp.223-231, 2004. ,
DOI : 10.1038/nri11308
URL : https://hal.archives-ouvertes.fr/pasteur-01402360
Effective antigen cross-presentation by prostate cancer patients' dendritic cells: implications for prostate cancer immunotherapy, Prostate Cancer and Prostatic Diseases, vol.7, issue.1, pp.63-72, 2004. ,
DOI : 10.1038/sj.pcan.4500694
URL : https://hal.archives-ouvertes.fr/pasteur-01402399
Monitoring of CD4+ and CD8+ T-Cell Responses After Dendritic Cell-Based Immunotherapy Using CFSE Dye Dilution Analysis, Journal of Clinical Immunology, vol.276, issue.5, pp.653-663, 2004. ,
DOI : 10.1007/s10875-004-6237-2
Immune and clinical responses in patients with metastatic melanoma to CD34(+) progenitor-derived dendritic cell vaccine, Cancer Res, vol.61, pp.6451-6458, 2001. ,
Dendritic Cells Injected Via Different Routes Induce Immunity in Cancer Patients, The Journal of Immunology, vol.166, issue.6, pp.4254-4259, 2001. ,
DOI : 10.4049/jimmunol.166.6.4254
Fully mobilizing host defense: building better vaccines, Nat Biotechnol, vol.16, pp.1025-1031, 1998. ,
Spontaneous Proliferation and Type 2 Cytokine Secretion by CD4+T Cells in Patients with Metastatic Melanoma Vaccinated with Antigen-Pulsed Dendritic Cells, Journal of Clinical Immunology, vol.16, issue.3, pp.288-295, 2005. ,
DOI : 10.1007/s10875-005-4089-z
Cancer immunosurveillance, immunoediting and inflammation: independent or interdependent processes?, Current Opinion in Immunology, vol.19, issue.2, pp.203-208, 2007. ,
DOI : 10.1016/j.coi.2007.02.001
The B7 Family and Cancer Therapy: Costimulation and Coinhibition, Clinical Cancer Research, vol.13, issue.18, pp.5271-5279, 2007. ,
DOI : 10.1158/1078-0432.CCR-07-1030
Potentiating Endogenous Antitumor Immunity to Prostate Cancer through Combination Immunotherapy with CTLA4 Blockade and GM-CSF, Cancer Research, vol.69, issue.2, pp.609-615, 2009. ,
DOI : 10.1158/0008-5472.CAN-08-3529
Principles and use of anti-CTLA4 antibody in human cancer immunotherapy, Current Opinion in Immunology, vol.18, issue.2, pp.206-213, 2006. ,
DOI : 10.1016/j.coi.2006.01.011
Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor alpha, Journal of Experimental Medicine, vol.179, issue.4, pp.1109-1118, 1994. ,
DOI : 10.1084/jem.179.4.1109
Prostaglandin E2 and Tumor Necrosis Factor ?? Cooperate to Activate Human Dendritic Cells: Synergistic Activation of Interleukin 12 Production, Journal of Experimental Medicine, vol.183, issue.4, pp.1603-1608, 1997. ,
DOI : 10.1084/jem.183.4.1447